Immune cells dictate tumour progression
Analysing individuals' genotypes and immunotypes could yield customised treatments for prostate cancer...
List view / Grid view
Analysing individuals' genotypes and immunotypes could yield customised treatments for prostate cancer...
Researchers identify a pathway that causes tumour acceleration in metastatic prostate cancer cells...
British scientists have investigated the impact of anti-hormone therapy on patients with prostate cancer...
Scientists have described a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA...
Patients who have aggressive prostate cancer could be identified by a highly accurate and simple blood test, according to a new study.
A new diagnostic will allow men to bypass painful biopsies to test for aggressive prostate cancer.
Screening for prostate cancer is controversial. It can save lives, but it can also lead to unnecessary diagnoses, followed by surgical or radiation procedures, which themselves may lead to severe side-effects.
10 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers have discovered that a marker found on aggressive prostate cancer cells could also be used as a way to guide treatments to the cancer...
5 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The loss of CHD1, one of the most mutated genes in prostate tumours, sensitises human prostate cancer cells to different drugs, a biomarker for...
1 May 2016 | By Victoria White, Digital Content Producer
Researchers found that Hsp90 inhibitors target and inactivate a mechanism commonly used by prostate cancer cells to evade the effects of standard treatment...
22 March 2016 | By Victoria White
The treatment is designed to inhibit the activity of a protein called PAK-1, which contributes to the development of highly invasive prostate cancer cells...
28 January 2016 | By Victoria White, Digital Content Producer, Drug Target Review
2015 was an exciting year for the drug discovery industry. Here we look at a selection of stories that particularly stood out for us…
22 December 2015 | By Victoria White
MDSCs are immune cells that “expand” when faced with cancer, inflammation or infections, giving them the unique ability to suppress the body’s T-cell response to disease...
18 November 2015 | By Victoria White
miR-124 hit multiple targets, reducing androgen receptor signalling and reviving the potency of advanced prostate cancer treatment Xtandi (enzalutamide)...
26 October 2015 | By Victoria White
The discovery could shed light on how prostate cancer spreads and provides a possible new target for the disease...